|
KMID : 1039320230230010225
|
|
Journal of Liver Cancer
2023 Volume.23 No. 1 p.225 ~ p.229
|
|
|
Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
|
|
Kim Yong-Tae
Kim Ji-Na
Seong Jin-Sil
|
|
|
Abstract
|
|
|
|
Recently, the superiority of atezolizumab plus bevacizumab (AteBeva) over sorafenib was proven in the IMbrave150 trial, and AteBeva became the first-line systemic treatment for untreated, unresectable hepatocellular carcinoma (HCC). While the results are encouraging, more than half of patients with advanced HCC are still being treated in a palliative setting. Radiotherapy (RT) is known to induce immunogenic effects that may enhance the therapeutic efficacy of immune checkpoint inhibitors. Herein, we report the case of a patient with advanced HCC with massive portal vein tumor thrombosis treated with a combination of RT and AteBeva, who showed near complete response in tumor thrombosis and favorable response to HCC. Although this is a rare case, it shows the importance of reducing the tumor burden via RT to combination immunotherapy in patients with advanced HCC.
|
|
|
KEYWORD
|
|
|
Hepatocellular carcinoma, Atezolizumab, Bevacizumab, Radiotherapy, Case reports
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|